Jump to content

Chronic lymphocytic leukemia

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by 96.232.103.102 (talk) at 04:20, 7 January 2014. The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

"B-cell CLL" redirects here. For the gene family, see B-cell CLL/lymphoma.
Chronic lymphocytic leukemia
SpecialtyHematology Edit this on Wikidata

B-cell chronic lymphocytic leukemia (B-CLL), also known as chronic lymphoid leukemia (CLL), is the most common type of leukemia.[citation needed] Leukemias are cancers of the white blood cells (leukocytes). CLL affects B cell lymphocytes. B cells originate in the bone marrow, develop in the lymph nodes, and normally fight infection by producing antibodies. In CLL, B cells grow out of control and accumulate in the bone marrow and blood, where they crowd out healthy blood cells. CLL is a stage of small lymphocytic lymphoma (SLL), a type of B-cell lymphoma, which presents primarily in the lymph nodes.[1] CLL and SLL are considered the same underlying disease, just with different appearances.

CLL is a disease of adults, but, in rare cases, it can occur in teenagers and occasionally in children (inherited). Most (>75%) people newly diagnosed with CLL are over the age of 50, and the majority are men.

Most people are diagnosed without symptoms as the result of a routine blood test that returns a high white blood cell count, but, as it advances, CLL results in swollen lymph nodes, spleen, and liver, and eventually anemia and infections. Early CLL is not treated, and late CLL is treated with chemotherapy and monoclonal antibodies.

DNA analysis has distinguished two major types of CLL, with different survival times. CLL that is positive for the marker ZAP-70 has an average survival of 8 years. CLL that is negative for ZAP-70 has an average survival of more than 25 years. Many patients, especially older ones, with slowly progressing disease can be reassured and may not need any treatment in their lifetimes.[2]

Symptoms and signs

Most people are diagnosed without symptoms as the result of a routine blood test that returns a high white blood cell count. Less commonly, CLL may present with enlarged lymph nodes without a high white blood cell count or no evidence of the disease in the blood. This is referred to as small lymphocytic lymphoma. In some individuals the disease comes to light only after the neoplastic cells overwhelm the bone marrow resulting in anemia producing tiredness or weakness.

Diagnosis

Micrograph of a lymph node affected by B-CLL showing a characteristic proliferation center (right of image), composed of larger, lighter staining, cells. H&E stain.

CLL is usually first suspected by the presence of a lymphocytosis, an increase in one type of white blood cell, on a complete blood count (CBC) test. This frequently is an incidental finding on a routine physician visit. Most often the lymphocyte count is greater than 4000 cells per microliter (µl) of blood, but can be much higher. The presence of a lymphocytosis in an elderly individual should raise strong suspicion for CLL, and a confirmatory diagnostic test, in particular flow cytometry, should be performed unless clinically unnecessary.

The diagnosis of CLL is based on the demonstration of an abnormal population of B lymphocytes in the blood, bone marrow, or tissues that display an unusual but characteristic pattern of molecules on the cell surface. This atypical molecular pattern includes the coexpression of cells surface markers cluster of differentiation 5 (CD5) and cluster of differentiation 23 (CD23). In addition, all the CLL cells within one individual are clonal, that is, genetically identical. In practice, this is inferred by the detection of only one of the mutually exclusive antibody light chains, kappa or lambda, on the entire population of the abnormal B cells. Normal B lymphocytes consist of a stew of different antibody-producing cells, resulting in a mixture of both kappa and lambda expressing cells. The lack of the normal distribution of kappa and lambda producing B cells is one basis for demonstrating clonality, the key element for establishing a diagnosis of any B cell malignancy (B cell non-Hodgkin lymphoma).

The combination of the microscopic examination of the peripheral blood and analysis of the lymphocytes by flow cytometry to confirm clonality and marker molecule expression is needed to establish the diagnosis of CLL. Both are easily accomplished on a small amount of blood. A flow cytometer is an instrument that can examine the expression of molecules on individual cells in fluids. This requires the use of specific antibodies to marker molecules with fluorescent tags recognized by the instrument. In CLL, the lymphocytes are genetically clonal, of the B cell lineage (expressing marker molecules cluster of differentiation 19 (CD19) and CD20), and characteristically express the marker molecules CD5 and CD23. These B cells resemble normal lymphocytes under the microscope, although slightly smaller, and are fragile when smeared onto a glass slide, giving rise to many broken cells, which are called smudge, or smear cells.[3]

Smear cells in peripheral blood

Clinical staging

Staging, determining the extent of the disease, is done with the Rai staging system or the Binet classification (see details[4]) and is based primarily on the presence of a low platelet or red cell count. Early stage disease does not need to be treated.

Gene mutation status

IgVH mutation status

Prognosis varies greatly depending on which diagnostic group CLL falls into. There are two[5] or three[6] prognostic groups based on the maturational state of the cell. This distinction is based on the maturity of the lymphocytes as discerned by the immunoglobulin variable-region heavy chain (IgVH) gene mutation status.[7] High risk patients have an immature cell pattern with few mutations in the DNA in the IgVH antibody gene region whereas low risk patients show considerable mutations of the DNA in the antibody gene region indicating mature lymphocytes.[8] Moreover, usage of specific subgenes (i.e. V3-21) for variable seqment of immunoglobulin is a marker for more severe prognosis.[9] The usage of certain variable seqments (i.e. V2 family) is also connected to the activation of microRNA miR-650, which further influences the biology of CLL.[10]

Since assessment of the IgVH antibody DNA changes is difficult to perform, the presence of either cluster of differentiation 38 (CD38) or Z-chain–associated protein kinase-70 (ZAP-70) may be surrogate markers of high risk subtype of CLL.[7] Their expression correlates with a more immature cellular state and a more rapid disease course.

Fluorescence in situ hybridization

In addition to the immunoglobulin variable-region heavy chain (IgVH) gene mutation status, the prognosis of patients with CLL is dependent on the genetic changes within the neoplastic cell population. These genetic changes can be identified by fluorescent probes to chromosomal parts using a technique referred to as fluorescent in situ hybridization (FISH).[7] Four main genetic aberrations are recognized in CLL cells that have a major impact on disease behavior.[11]

  1. Deletions of part of the short arm of chromosome 17 (del 17p), which target the cell cycle regulating protein p53 are particularly deleterious. The deletion of p53 leads to deregulation of numerous genes including microRNAs (miR-34a).[12] Patients with this abnormality have significantly short interval before they require therapy and a shorter survival. This abnormality is found in 5–10% of patients with CLL.
  2. Deletions of the long arm on chromosome 11 (del 11q) are also unfavorable although not to the degree seen with del 17p. The abnormality targets the ATM gene and occurs infrequently in CLL (5–10%).
  3. Trisomy 12, an additional chromosome 12, is a relatively frequent finding occurring in 20–25% of patients and imparts an intermediate prognosis.
  4. Deletion of the long arm of chromosome 13 (del 13q) is the most common abnormality in CLL with roughly 50% of patients with cells containing this defect. These patients have the best prognosis and most will live many years, even decades, without the need for therapy. The gene targeted by this deletion is a segment coding for microRNAs miR-15a and miR-16-1.[13][14]

Array-based karyotyping

Array-based karyotyping is a cost-effective alternative to FISH for detecting chromosomal abnormalities in CLL. Several clinical validation studies have shown >95% concordance with the standard CLL FISH panel.[15][16][17][18][19] See also Virtual Karyotype.

In the past, cases with similar microscopic appearance in the blood but with a T cell phenotype were referred to as T-cell CLL. These so-called T-cell CLLs, however, are now recognized as a separate disease group and are currently classified as T-cell prolymphocytic leukemias.[20][21]

CLL should not be confused with acute lymphoblastic leukemia (ALL), a highly aggressive leukemia most commonly diagnosed in children, and highly treatable in the pediatric setting.

Differential diagnosis

Hematologic disorders that may resemble CLL in their clinical presentation, behavior, and microscopic appearance include mantle cell lymphoma, marginal zone lymphoma, B cell prolymphocytic leukemia, and lymphoplasmacytic lymphoma.

  • B cell prolymphocytic leukemia (B PLL), a related, but more aggressive disorder, has cells with similar phenotype, but are significantly larger than normal lymphocytes and have a prominent nucleolus. The distinction is important as the prognosis and therapy differs from CLL.
  • Hairy cell leukemia is also a neoplasm of B lymphocytes, but the neoplastic cells have a distinct morphology under the microscope (hairy cell leukemia cells have delicate, hair-like projections on their surface) and unique marker molecule expression.

All the B cell malignancies of the blood and bone marrow can be differentiated from one another by the combination of cellular microscopic morphology, marker molecule expression, and specific tumor-associated gene defects. This is best accomplished by evaluation of the patient's blood, bone marrow and occasionally lymph node cells by a pathologist with specific training in blood disorders. A flow cytometer is necessary for cell marker analysis, and the detection of genetic problems in the cells may require visualizing the DNA changes with fluorescent probes by FISH.

Treatment

CLL treatment focuses on controlling the disease and its symptoms rather than on an outright cure. CLL is treated by chemotherapy, radiation therapy, biological therapy, or bone marrow transplantation. Symptoms are sometimes treated surgically (splenectomy removal of enlarged spleen) or by radiation therapy ("de-bulking" swollen lymph nodes).

Initial CLL treatments vary depending on the exact diagnosis and the progression of the disease, and even with the preference and experience of the health care practitioner. There are dozens of agents used for CLL therapy.[22] An initial treatment regimen that contains fludarabine, cyclophosphamide, and rituximab (known as FCR) has demonstrated higher overall response rates and complete response rates.[23]

During pregnancy

Leukemia is rarely associated with pregnancy, affecting only about 1 in 10,000 pregnant women.[24] Treatment for chronic lymphocytic leukemias can often be postponed until after the end of the pregnancy. If treatment is necessary, then giving chemotherapy during the second or third trimesters is less likely to result in pregnancy loss or birth defects than treatment during the first trimester.[24]

Decision to treat

While generally considered incurable, CLL progresses slowly in most cases. Many people with CLL lead normal and active lives for many years—in some cases for decades. Because of its slow onset, early-stage CLL is, in general, not treated since it is believed that early CLL intervention does not improve survival time or quality of life. Instead, the condition is monitored over time to detect any change in the disease pattern.[23]

The decision to start CLL treatment is taken when the patient's clinical symptoms or blood counts indicate that the disease has progressed to a point where it may affect the patient's quality of life.

Clinical "staging systems" such as the Rai 4-stage system and the Binet classification can help to determine when and how to treat the patient.[4]

Determining when to start treatment and by what means is often difficult; studies have shown there is no survival advantage to treating the disease too early. The National Cancer Institute Working Group has issued guidelines for treatment, with specific markers that should be met before it is initiated.[25]

Chemotherapy

Combination chemotherapy regimens are effective in both newly-diagnosed and relapsed CLL. Combinations of fludarabine with alkylating agents (cyclophosphamide) produce higher response rates and a longer progression-free survival than single agents:

Although the purine analogue fludarabine was shown to give superior response rates to chlorambucil as primary therapy,[29][30] there is no evidence early use of fludarabine improves overall survival, and some clinicians prefer to reserve fludarabine for relapsed disease.

Chemoimmunotherapy with FCR has shown to improve response rates, progression-free survival and overall survival in a large randomized trial in CLL patients selected for good physical fitness.[31] This has been the first clinical trial demonstrating that the choice of a first line therapy can improve the overall survival of patients with CLL.

Alkylating agents approved for CLL include bendamustine and cyclophosphamide.

Monoclonal antibodies, such as alemtuzumab (directed against CD52) and rituximab and ofatumumab (directed against CD20), are also used.[23]

Stem cell transplantation

Allogeneic bone marrow (stem cell) transplantation is rarely used as a first-line treatment for CLL due to its risk. There is increasing interest in the use of reduced-intensity allogeneic stem cell transplantation, which offers the prospect of cure for selected patients with a suitable donor.[32]

Younger patients that are at high risk for dying from CLL might consider hematopoietic stem cell transplantation (HSCT). Autologous stem cell transplantation, a lower-risk form of treatment using the patient's own blood cells, is not curative. Myeloablative (bone marrow killing) forms of allogeneic stem cell transplantation, a high-risk treatment using blood cells from a healthy donor, may be curative for some patients, but most patients cannot tolerate the treatment. An intermediate level, called reduced-intensity conditioning allogeneic stem cell transplantation, may be better tolerated by older or frail patients.[33]

Refractory CLL

"Refractory" CLL is a disease that no longer responds favorably to treatment. In this case more aggressive therapies, including lenalidomide, flavopiridol, and bone marrow (stem cell) transplantation, are considered.[34] The monoclonal antibody, alemtuzumab (directed against CD52), may be used in patients with refractory, bone marrow-based disease.[35]

Complications

Complications include Richter's syndrome, hypogammaglobulinemia leading to recurrent infection, warm autoimmune hemolytic anemia in 10–15% of patients, transformation to high grade lymphoma.

Chronic lymphocytic leukemia may transform into Richter's syndrome, the development of fast-growing diffuse large B cell lymphoma, prolymphocytic leukemia, Hodgkin's lymphoma, or acute leukemia in a patient who has chronic lymphocytic leukemia. Its incidence is estimated to be around 5 percent in patients with CLL.[36]

Gastrointestinal (GI) involvement can rarely occur with chronic lymphocytic leukemia. Some of the reported manifestations include intussusception, small intestinal bacterial contamination, colitis and others. Usually, GI complications with CLL occur after Richter transformation. There have been two case reports to date of GI involvement in chronic lymphocytic leukemia without Richter's transformation.[37]

Epidemiology

CLL is primarily a disease of older adults, with a median age of 70 years at the time of diagnosis.[38] Though less common, CLL sometimes affects people between 30 and 39 years of age. The incidence of CLL increases very quickly with increasing age.

In the United States during 2012, about 16,060 new cases are expected to be diagnosed, and 4,580 patients are expected to die from CLL.[39] Because of the prolonged survival, which was typically about ten years in past decades, but which can extend to a normal life expectancy,[4] the prevalence (number of people living with the disease) is much higher than the incidence (new diagnoses).

CLL is very rare in Asian countries, such as Japan and China, and may account for as few as 10 percent of all leukemias in those regions.[38]

Subclinical "disease" can be identified in 3.5% of normal adults,[40] and in up to 8% of individuals over the age of 70[citation needed]. That is, small clones of B cells with the characteristic CLL phenotype can be identified in many healthy elderly persons. The clinical significance of these cells is unknown.

Of all cancers involving the same class of blood cell, 7% of cases are CLL/SLL.[41]

Rates of CLL are somewhat elevated in people exposed to certain chemicals. Under U.S. Department of Veterans' Affairs regulations, Vietnam veterans who served in-country or in the inland waterways of Vietnam and who later develop CLL are presumed to have contracted it from exposure to Agent Orange and may be entitled to compensation.[42]

Prognosis

Prognosis depends on the subtype. Some subtypes have a median survival of 6–8 years, while others have a median survival of 22 years (which is a normal lifespan for older patients).[citation needed] Telomere length has been suggested to be a valuable prognostic indicator of survival.[43]

Research directions

Considerable research activity, studying the many treatments individually or in combination, is ongoing.[22] Current research is comparing different forms of bone marrow transplants to determine which patients are the best candidates and which approach is best in different situations.[33]

Wikinews has related news:

Researchers at the Abramson Cancer Center of the University of Pennsylvania School of Medicine reported preliminary success in the use of gene therapy, through genetically modified T cells, to treat CLL.[44] The findings, which were published in August 2011,[45][46] were based on data from three patients who had modified T cells injected into their blood. The T cells had been modified to express genes that would allow the cells to proliferate in the body and destroy B cells including those causing the leukemia. Two patients went into remission, while the presence of leukemia in the third patient reduced by 70 percent.[47][48] One of the patients had been diagnosed with CLL for 13 years, and his treatment was failing before he participated in the clinical trial. One week after the T cells were injected, the leukemia cells in his blood had disappeared.[49] The T cells were still found in the bloodstream of the patients six months after the procedure, meaning they would be able to fight the disease should leukemia cells return.[47] This was the first time scientists "have used gene therapy to successfully destroy cancer tumors in patients with advanced disease".[50] One editorial in The New England Journal of Medicine also urged caution because only more trials would indicate whether the findings are "an authentic advance toward a clinically applicable and effective therapy".[51][52]

See also

References

  1. ^ Harris NL; Jaffe ES; Diebold J; et al. (1999). "World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997". J. Clin. Oncol. 17 (12): 3835–49. PMID 10577857. {{cite journal}}: Unknown parameter |author-separator= ignored (help)
  2. ^ Chiorazzi N, Rai KR, Ferrarini M (2005). "Chronic lymphocytic leukemia". N. Engl. J. Med. 352 (8): 804–15. doi:10.1056/NEJMra041720. PMID 15728813.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  3. ^ Bain, Barbara J. (2006). Blood Cells: A Practical Guide. Blackwell Publishing Limited. p. 439. ISBN 1-4051-4265-0.
  4. ^ a b c National Cancer Institute. "Chronic Lymphocytic Leukemia (PDQ) Treatment: Stage Information". Archived from the original on 17 October 2007. Retrieved 2007-09-04. {{cite web}}: Unknown parameter |deadurl= ignored (|url-status= suggested) (help)
  5. ^ Rosenwald A; Alizadeh AA; Widhopf G; et al. (2001). "Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia". J. Exp. Med. 194 (11): 1639–47. doi:10.1084/jem.194.11.1639. PMC 2193523. PMID 11733578. {{cite journal}}: Unknown parameter |author-separator= ignored (help)
  6. ^ Ghia P; Guida G; Stella S; et al. (2003). "The pattern of CD38 expression defines a distinct subset of chronic lymphocytic leukemia (CLL) patients at risk of disease progression". Blood. 101 (4): 1262–9. doi:10.1182/blood-2002-06-1801. PMID 12406914. {{cite journal}}: Unknown parameter |author-separator= ignored (help)
  7. ^ a b c Shanafelt TD, Byrd JC, Call TG, Zent CS, Kay NE (2006). "Narrative review: initial management of newly diagnosed, early-stage chronic lymphocytic leukemia". Ann. Intern. Med. 145 (6): 435–47. PMID 16983131.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  8. ^ Hamblin TJ; Davis Z; Gardiner A; et al. (1999). "Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia". Blood. 94 (6): 1848–54. PMID 10477713. {{cite journal}}: Unknown parameter |author-separator= ignored (help)
  9. ^ Attention: This template ({{cite pmid}}) is deprecated. To cite the publication identified by PMID 11877310, please use {{cite journal}} with |pmid=11877310 instead.
  10. ^ Attention: This template ({{cite pmid}}) is deprecated. To cite the publication identified by PMID 22234685, please use {{cite journal}} with |pmid=22234685 instead.
  11. ^ Dohner H; Stilgenbauer S; Benner A; ""; et al. (2000). "Genomic aberrations and survival in chronic lymphocytic leukemia". NEJM. 343 (26): 1910–6. doi:10.1056/NEJM200012283432602. PMID 11136261. {{cite journal}}: |author4= has numeric name (help); Unknown parameter |author-separator= ignored (help)
  12. ^ Attention: This template ({{cite pmid}}) is deprecated. To cite the publication identified by PMID 19158830, please use {{cite journal}} with |pmid=19158830 instead.
  13. ^ Attention: This template ({{cite pmid}}) is deprecated. To cite the publication identified by PMID 19347736, please use {{cite journal}} with |pmid=19347736 instead.
  14. ^ Attention: This template ({{cite pmid}}) is deprecated. To cite the publication identified by PMID 23216588, please use {{cite journal}} with |pmid=23216588 instead.
  15. ^ Lehmann S; Ogawa S; Raynaud SD; et al. (2008). "Molecular allelokaryotyping of early-stage, untreated chronic lymphocytic leukemia". Cancer. 112 (6): 1296–305. doi:10.1002/cncr.23270. PMID 18246537. {{cite journal}}: Unknown parameter |author-separator= ignored (help); Unknown parameter |month= ignored (help)
  16. ^ Sargent R; Jones D; Abruzzo LV; et al. (2009). "Customized oligonucleotide array-based comparative genomic hybridization as a clinical assay for genomic profiling of chronic lymphocytic leukemia". J Mol Diagn. 11 (1): 25–34. doi:10.2353/jmoldx.2009.080037. PMC 2607562. PMID 19074592. {{cite journal}}: Unknown parameter |author-separator= ignored (help); Unknown parameter |month= ignored (help)
  17. ^ Schwaenen C; Nessling M; Wessendorf S; et al. (2004). "Automated array-based genomic profiling in chronic lymphocytic leukemia: development of a clinical tool and discovery of recurrent genomic alterations". Proc. Natl. Acad. Sci. U.S.A. 101 (4): 1039–44. doi:10.1073/pnas.0304717101. PMC 327147. PMID 14730057. {{cite journal}}: Unknown parameter |author-separator= ignored (help); Unknown parameter |month= ignored (help)
  18. ^ Pfeifer D; Pantic M; Skatulla I; et al. (2007). "Genome-wide analysis of DNA copy number changes and LOH in CLL using high-density SNP arrays". Blood. 109 (3): 1202–10. doi:10.1182/blood-2006-07-034256. PMID 17053054. {{cite journal}}: Unknown parameter |author-separator= ignored (help); Unknown parameter |month= ignored (help)
  19. ^ Gunn SR; Mohammed MS; Gorre ME; et al. (2008). "Whole-genome scanning by array comparative genomic hybridization as a clinical tool for risk assessment in chronic lymphocytic leukemia". J Mol Diagn. 10 (5): 442–51. doi:10.2353/jmoldx.2008.080033. PMC 2518739. PMID 18687794. {{cite journal}}: Unknown parameter |author-separator= ignored (help); Unknown parameter |month= ignored (help)
  20. ^ "T Cell Prolymphocytic Leukemia". AccessMedicine. Retrieved 2009-02-04.
  21. ^ Ascani S; Leoni P; Fraternali Orcioni G; et al. (1999). "T-cell prolymphocytic leukaemia: does the expression of CD8+ phenotype justify the identification of a new subtype? Description of two cases and review of the literature". Ann. Oncol. 10 (6): 649–53. doi:10.1023/A:1008349422735. PMID 10442186. {{cite journal}}: Unknown parameter |author-separator= ignored (help); Unknown parameter |month= ignored (help)
  22. ^ a b National Cancer Institute. "Chronic Lymphocytic Leukemia (PDQ) Treatment: Stage I, II, III, and IV Chronic Lymphocytic Leukemia". Archived from the original on 17 October 2007. Retrieved 2007-09-04. {{cite web}}: Unknown parameter |deadurl= ignored (|url-status= suggested) (help)
  23. ^ a b c Janssens; et al. (2011). "Rituximab for Chronic Lymphocytic Leukemia in Treatment-Naïve and Treatment-Experienced Patients". Contemporary Oncology. 3 (3): 24–36. {{cite journal}}: Explicit use of et al. in: |author= (help)
  24. ^ a b Shapira T, Pereg D, Lishner M (2008). "How I treat acute and chronic leukemia in pregnancy". Blood Rev. 22 (5): 247–59. doi:10.1016/j.blre.2008.03.006. PMID 18472198. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  25. ^ Cheson BD; Bennett JM; Grever M; et al. (1996). "National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment". Blood. 87 (12): 4990–7. PMID 8652811. {{cite journal}}: Unknown parameter |author-separator= ignored (help)
  26. ^ Eichhorst BF, Busch R, Hopfinger G, Pasold R, Hensel M, Steinbrecher C, Siehl S, Jäger U, Bergmann M, Stilgenbauer S, Schweighofer C, Wendtner CM, Döhner H, Brittinger G, Emmerich B, Hallek M, German CLL Study Group. (2006). "Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia". Blood. 107 (3): 885–91. doi:10.1182/blood-2005-06-2395. PMID 16219797.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  27. ^ Byrd JC; Peterson BL; Morrison VA; et al. (2003). "Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712)". Blood. 101 (1): 6–14. doi:10.1182/blood-2002-04-1258. PMID 12393429. {{cite journal}}: Unknown parameter |author-separator= ignored (help)
  28. ^ Keating MJ; O'Brien S; Albitar M; et al. (2005). "Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia". J. Clin. Oncol. 23 (18): 4079–88. doi:10.1200/JCO.2005.12.051. PMID 15767648. {{cite journal}}: Unknown parameter |author-separator= ignored (help)
  29. ^ Rai KR; Peterson BL; Appelbaum FR; et al. (2000). "Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia". N. Engl. J. Med. 343 (24): 1750–7. doi:10.1056/NEJM200012143432402. PMID 11114313. {{cite journal}}: Unknown parameter |author-separator= ignored (help)
  30. ^ Steurer M, Pall G, Richards S, Schwarzer G, Bohlius J, Greil R (2006). Steurer, Michael (ed.). "Purine antagonists for chronic lymphocytic leukaemia". Cochrane database of systematic reviews (Online). 3: CD004270. doi:10.1002/14651858.CD004270.pub2. PMID 16856041.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  31. ^ Hallek, M., Fischer, K., Fingerle-Rowson, G., Fink, A.M., Busch, R., Mayer, J., Hensel, M., Hopfinger, G., Hess, G., von Grunhagen, U., et al. (2010). Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 376, 1164-1174.
  32. ^ Dreger P, Brand R, Hansz J, Milligan D, Corradini P, Finke J, Deliliers GL, Martino R, Russell N, Van Biezen A, Michallet M, Niederwieser D; Chronic Leukemia Working Party of the EBMT (2003). "Treatment-related mortality and graft-versus-leukemia activity after allogeneic stem cell transplantation for chronic lymphocytic leukemia using intensity-reduced conditioning". Leukemia. 17 (5): 841–8. doi:10.1038/sj.leu.2402905. PMID 12750695.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  33. ^ a b Gribben JG (2008). "Stem cell transplantation in chronic lymphocytic leukemia". Biol. Blood Marrow Transplant. 15 (1 Suppl): 53–8. doi:10.1016/j.bbmt.2008.10.022. PMC 2668540. PMID 19147079. {{cite journal}}: Unknown parameter |month= ignored (help)
  34. ^ National Cancer Institute. "Chronic Lymphocytic Leukemia (PDQ) Treatment: Refractory Chronic Lymphocytic Leukemia". Archived from the original on 17 October 2007. Retrieved 2007-09-04. {{cite web}}: Unknown parameter |deadurl= ignored (|url-status= suggested) (help)
  35. ^ Keating MJ, Flinn I, Jain V, Binet JL, Hillmen P, Byrd J, Albitar M, Brettman L, Santabarbara P, Wacker B, Rai KR (2002). "Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study". Blood. 99 (10): 3554–61. doi:10.1182/blood.V99.10.3554. PMID 11986207.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  36. ^ Tsimberidou AM, Keating MJ (2005). "Richter syndrome: biology, incidence, and therapeutic strategies". Cancer. 103 (2): 216–28. doi:10.1002/cncr.20773. PMID 15578683. {{cite journal}}: Unknown parameter |month= ignored (help)
  37. ^ Bitetto AM, Lamba G, Cadavid G, Shah D, Forlenza T, Rotatori F, Rafiyath SM. Colonic perforation secondary to chronic lymphocytic leukemia infiltration without Richter transformation. Leuk Lymphoma. 2011 May;52(5):930-3.
  38. ^ a b Shanshal, Mohammed (2012). "Chronic Lymphocytic Leukemia". Disease-a-Month. 58 (4): 153–167. doi:10.1016/j.disamonth.2012.01.009. PMID 22449365. {{cite journal}}: |access-date= requires |url= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help); Unknown parameter |month= ignored (help)
  39. ^ National Cancer Institute. "General Information About Chronic Lymphocytic Leukemia". Retrieved 2007-09-04. {{cite web}}: Unknown parameter |deadurl= ignored (|url-status= suggested) (help)
  40. ^ Rawstron AC; Green MJ; Kuzmicki A; et al. (2002). "Monoclonal B lymphocytes with the characteristics of "indolent" chronic lymphocytic leukemia are present in 3.5% of adults with normal blood counts". Blood. 100 (2): 635–9. doi:10.1182/blood.V100.2.635. PMID 12091358. {{cite journal}}: Unknown parameter |author-separator= ignored (help); Unknown parameter |month= ignored (help)
  41. ^ Turgeon, Mary Louise (2005). Clinical hematology: theory and procedures. Hagerstown, MD: Lippincott Williams & Wilkins. p. 283. ISBN 0-7817-5007-5. Frequency of lymphoid neoplasms. (Source: Modified from WHO Blue Book on Tumour of Hematopoietic and Lymphoid Tissues. 2001, p. 2001.)
  42. ^ http://ecfr.gpoaccess.gov/cgi/t/text/text-idx?c=ecfr&sid=150fea5ac37ad66e06bdb4f940a0e0dc&rgn=div8&view=text&node=38:1.0.1.1.4.1.65.117&idno=38>
  43. ^ Rossi, D (June 2009). "Telomere length is an independent predictor of survival, treatment requirement and Richter's syndrome transformation in chronic lymphocytic leukemia". Leukemia. 23 (6): 1062–72. PMID 19340005. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
  44. ^ Auer, Holly (August 10, 2011). "Genetically Modified "Serial Killer" T Cells Obliterate Tumors in Patients with Chronic Lymphocytic Leukemia, Penn Researchers Report". University of Pennsylvania School of Medicine. Retrieved August 12, 2011.
  45. ^ Porter DL; et al. (2011). "Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia". N. Engl. J. Med. 365 (8): 110810110014063. doi:10.1056/NEJMoa1103849. PMC 3387277. PMID 21830940. {{cite journal}}: Unknown parameter |author-separator= ignored (help)
  46. ^ Kalos M; et al. (2011). "T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia". Sci. Transl. Med. 3 (95): 95ra73. doi:10.1126/scitranslmed.3002842. PMID 21832238. {{cite journal}}: Unknown parameter |author-separator= ignored (help)
  47. ^ a b Palca, Joe (August 11, 2011). "Gene Therapy Advance Trains Immune System To Fight Leukemia". NPR. Retrieved August 12, 2011.
  48. ^ Bazell, Robert (August 10, 2011). "New leukemia treatment exceeds 'wildest expectations'". MSNBC. Retrieved August 12, 2011.
  49. ^ DeNoon, Daniel J. (August 10, 2011). "Gene Therapy Cures Adult Leukemia". WebMD. Retrieved August 12, 2011.
  50. ^ Beasly, Deena (August 10, 2011). "Gene therapy shown to destroy leukemia tumors". Reuters. Retrieved August 12, 2011.
  51. ^ "Treatment for Leukemia Is Showing Early Promise". The New York Times. Associated Press. August 11, 2011. p. A15. Retrieved August 12, 2011.
  52. ^ Urba WJ; et al. (2011). "Redirecting T Cells". N. Engl. J. Med. 365 (8): 110810110014063. doi:10.1056/NEJMe1106965. PMID 21830939. {{cite journal}}: Unknown parameter |author-separator= ignored (help)

Template:Smallblueroundcelltumors

Retrieved from "https://en.wikipedia.org/w/index.php?title=Chronic_lymphocytic_leukemia&oldid=589547362"